Ixazomib in the management of relapsed multiple myeloma - Inserm - Institut national de la santé et de la recherche médicale Access content directly
Journal Articles Future Oncology Year : 2018

Ixazomib in the management of relapsed multiple myeloma

Abstract

The development of proteasome inhibitors contributed to the dramatic life expectancy improvement observed in myeloma patients over the past decades. Ixazomib is a boron-containing selective and reversible proteasome inhibitor that demonstrated antimyeloma activity with excellent safety profile. Ixazomib is the first orally available proteasome inhibitor approved in combination with lenalidomide and dexam-ethasone for the treatment of myeloma patients who received at least one prior therapy. The present review addresses the current knowledge regarding the clinical use of ixazomib in relapsed myeloma patients .

Domains

Cancer
Embargoed file
Embargoed file
Ne sera jamais visible
Loading...

Dates and versions

inserm-01934497 , version 1 (26-11-2018)

Identifiers

Cite

Cyrille Touzeau, Philippe Moreau. Ixazomib in the management of relapsed multiple myeloma. Future Oncology, 2018, 14 (20), pp.2013 - 2020. ⟨10.2217/fon-2017-0710⟩. ⟨inserm-01934497⟩
107 View
1 Download

Altmetric

Share

Gmail Facebook X LinkedIn More